GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company focused on developing immune-oncology products, particularly its Tri-specific Killer Engager (TriKE) platform technology, which aims to harness natural killer (NK) cells to target cancer.1
When considering an investment in a clinical-stage biotech like GTBP, several data points from Fintel can provide valuable context:
- Analyst Sentiment and Price Target: The average one-year price target for GTBP is $11.22, with a range from $11.11 to $11.55.1 This suggests a significant potential upside from its current share price of $1.83 as of August 7, 2025.1 Analysts from HC Wainwright & Co. have maintained a "Buy" rating, while EF Hutton has maintained a "Hold" rating.1
- Institutional Ownership: GTBP has seen an increase in institutional interest, with 27 institutional owners holding a total of 198,439 shares.2 The number of institutional owners increased by 8.00% in the most recent quarter.2 Major institutions like Bank Of Montreal, Geode Capital Management, and Vanguard Group Inc. are among the largest shareholders.2
- Short Interest: The stock has a short interest of 273,519 shares, with a Short Interest % Float of 15.41% and 5.17 Days to Cover.3 A high borrow rate of 86.37% indicates significant demand to short the stock.1 This could imply market skepticism but also potential for a short squeeze if positive catalysts emerge.
- Financial Health: As a clinical-stage company, GTBP is currently unprofitable, with an EPS (TTM) of -4.60.1 Its Piotroski F-SCORE is low at 2.00 out of 9, reflecting financial characteristics typical of early-stage biotechs.1 However, forecasted annual revenue for 2030 is 444MM, indicating long-term growth expectations.4
Investing in clinical-stage biopharma companies carries inherent risks due to the binary nature of clinical trial outcomes and regulatory approvals. It is crucial to monitor their clinical pipeline progress and financial runway.
